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KEY POINTS 
• Although some atypical anti-psychotic drugs, particularly olanzapine and 
clozapine, have more severe weight gain side-effects, all anti-psychotics 
including typical anti-psychotics currently used clinically may cause some 
degree of weight gain.  
• There are time-dependent changes of weight gain associated with anti-
psychotic medication with a three stage time-course development; particularly 
rapid weight gain in the initial stage is a good indicator for a long-term 
outcome of weight gain and obesity. 
• Accumulated data suggest that increasing appetite and food intake, as well as 
delayed satiety signalling, are key behavioural changes related to weight 
gain/obesity induced by anti-psychotics. 
• Anti-psychotics may induce insulin resistance, glucose dysregulation, and even 
type II diabetes mellitus independent of weight gain and adiposity. 
• There are also time-dependent changes for insulin and glucose dysregulation 
associated with anti-psychotic medication. 
• Current evidence from clinical trials in first episode psychotic patients shows 
typical anti-psychotics such as haloperidol have relatively high risk for weight 
gain/obesity and glucometabolic side-effects.  
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• Monitoring weight gain is important but not enough. A periodic monitoring of 
blood sugar may also be required during anti-psychotic therapy, particularly for 
drugs with high diabetic liabilities such as olanzapine and clozapine. 
• There are marked individual variations in weight gain and other metabolic side-
effects associated with anti-psychotics. For example, irrespective of the anti-
psychotic drug, some patients lose weight, some maintain weight and some 
gain weight. 
• Mechanisms for anti-psychotic related weight gain, insulin resistance and 
glucose dysregulation have yet to be elucidated. Current results suggest that 
antagonistic effects of atypical anti-psychotics on serotonin 5-HT2C and 
histamine H1 receptors play an important role in weight gain/obesity side-
effects, whereas muscarinic M3 receptors have been identified as most closely 
linked with diabetic side-effects. However, blockade of dopamine D2 receptors 
may be a common mechanism for these metabolic side-effects in both atypical 
and typical anti-psychotics.  
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INTRODUCTION 
Mental disorders are the greatest overall cause of disability.1 Anti-psychotic drugs 
(APDs) are the most widely prescribed medications and are used frequently to control 
various mental disorders such as schizophrenia, bipolar disorder, dementia, major 
depression, Tourette’s syndrome, eating disorders and even substance abuse.2, 3 
Unfortunately, APDs may cause some serious side-effects including extra-pyramidal 
and metabolic side-effects. Since typical APDs were introduced into clinics in the 
1950s, their side-effects of increasing body weight have been reported, but have 
gained less attention because these drugs often have worse and problematic extra-
pyramidal side-effects.4 In the 1980s-1990s, clozapine, olanzapine and other atypical 
APDs with reduced extra-pyramidal side-effects were widely introduced into 
psychiatric clinics and currently form the first line of APD treatment.5, 6 
Unfortunately, atypical APDs, particularly clozapine and olanzapine, cause serious 
metabolic side-effects, such as substantial weight gain, intra-abdominal obesity, 
hyperlipidemia, insulin resistance, hyperglycemia, and type II diabetes mellitus 
(T2DM).7-10 These adverse effects are a major risk for cardiovascular disease, stroke 
and premature death (by 20-30 years).7, 11 In addition to medical consequences, 
weight gain and obesity can lead to non-compliance with medication - a primary 
problem for the treatment of schizophrenia, since cessation of APD treatment 
dramatically (up to 5-times) increases the relapse rate for these patients.12, 13  Given 
that the majority of patients with psychiatric disorders face chronic, even life-long, 
treatment with APDs, the risks of weight gain/obesity and other metabolic symptoms 
are major considerations for individual APD maintenance treatment. This review will 
focus on the effects of APDs on weight gain, appetite, insulin resistance and glucose 
dysregulation, as well as relevant underlying mechanisms that may be help to prevent 
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and treat weight gain, obesity, and other metabolic side-effects caused by APD 
therapy. 
 
WEIGHT GAIN AND OBESITY INDUCED BY ANTI-PSYCHOTICS 
Weight gain/obesity side-effects: Typical vs Atypical APDs. It had been reported 
since the 1950s that treatment with some typical APDs (such as chlorpromazine) is 
associated with weight gain, however many psychiatrists still believe that atypical 
APDs are associated with significant weight gain and obesity side-effects, but typical 
APDs are not.14 For example, the commonly used typical APD, haloperidol, was once 
believed to have a minimal weight gain side-effect.14 However, a recent report on the 
European First-Episode Schizophrenia Trial (EUFEST) has clearly shown that one 
year treatment with haloperidol caused clinically significant weight gain (≥ 7% from 
baseline) in 53% of patients, with an average weight gain of 7.3 kg.15 A dramatic 
weight gain (9.56 kg) was also observed in another study of first episode patients with 
1 year treatment with haloperidol.16 Therefore, while certain atypical APDs (such as 
olanzapine and clozapine) might lead to greater weight gain, typical APDs could also 
lead to significant weight and other metabolic changes in patients. 
 
Underestimation of weight gain and obesity side-effects has also been the case for 
atypical APDs. In 2005, the NIH funded CATIE (The Clinical Anti-psychotic Trials 
of Intervention Effectiveness) study reported the effects of atypical APDs olanzapine, 
quetiapine, risperidone and ziprasidone on body weight over an 18 months period in 
chronic schizophrenia patients who had an average of over 14 years’ APD medication 
history.17 The CATIE study found that olanzapine treatment caused significant weight 
gain (≥ 7% from baseline) in a higher proportion of patients (30%) than quetiapine 
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(16%), risperidone (14%) and ziprasidone (7%). Patients treated with olanzapine also 
gained more weight (average add 0.9 kg (2 lb) per month) than patients treated with 
quetiapine (average add 0.23 kg (0.5 lb) per month) and risperidone (average add 0.18 
kg (0.4 lb) per month), while ziprasidone treated patients lost body weight (average 
lose 0.14 kg (-0.3 lb) per month).17  However, the subsequent EUFEST and CAFE 
(Comparison of Atypical Anti-psychotics for First Episode) studies showed that these 
atypical APDs caused more severe weight gain in first episode schizophrenia 
patients.15, 18 The CAFE study reported that after a 12 week treatment, significant 
weight gain (≥ 7% body weight) occurred in a large number of first episode 
schizophrenia patients treated with olanzapine (59.8%), compared to risperidone 
(32.5%) and quetiapine (29.2%). Furthermore, after 52 weeks’ treatment, 80% of 
olanzapine-treated patients gained ≥ 7% body weight (with an average 1.76 kg (3.88 
lb) per month), compared to 57.6% of risperidone- (with an average 1.28 kg (2.81 lb) 
per month) and 50% of quetiapine-treated (with an average 1.29 kg (2.85 lb) per 
month) patients.18 The EUFEST study confirmed that, after 12 months’ treatment, 
olanzapine caused the most significant weight gain in first episode schizophrenia (in 
86% of patients with an average 1.16kg (2.56 lb) per month) compared to quetiapine 
(in 65% of patients with an average 0.88kg (1.94 lb) per month), amisulpride (in 63% 
of patients with an average 0.81kg (1.78 lb) per month) and ziprasidone (in 37% of 
patients with an average 0.4 kg (0.88 lb) per month).15 In another study of first 
episode patients, dramatic weight gain was observed in all olanzapine (average 12.02 
kg), risperidone (8.99kg) and haloperidol (9.56kg) treatment for 1 year.16 It is 
interesting that ziprasidone and amisulpride have been widely regarded as atypical 
APDs with low weight gain risk in previous studies;10 ziprasidone was even found to 
cause weight loss in the CATIE study.17 Therefore, it is worth exploring why a lesser 
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weight gain side-effect was observed in the CATIE study. The main difference 
between these studies was that subjects in the CATIE study had a chronic APD 
medication history (average over 14 years) compared to first episode patients in the 
EUFEST and CAFE without previous APD medication.15, 17, 18 These clinical trials 
indicate that previous studies on chronic schizophrenia patients may have 
underestimated the magnitude of weight gain/obesity side-effects associated with 
APDs. Furthermore, although mean weight gain and the incidence of clinically 
significant weight gain may vary between APDs, olanzapine and clozapine have the 
highest risk; accumulated evidence indicates that both typical and atypical APDs have 
greater weight gain and other metabolic side-effects than placebo-level effects.9, 10, 15   
 
Time-course of APD-induced weight-gain/obesity. Although various APDs cause 
weight gain at different magnitudes, both typical and atypical APDs exhibit a similar 
temporal course of weight gain that includes three stages: Stage 1, an early 
acceleration stage in which APDs induce a rapid increase in body weight gain within 
the first few months of treatment (e.g. about 3 months for clozapine, olanzapine, 
risperidone, and haloperidol); Stage 2, a  middle stage in which body weight 
continues to increase at a much steadier rate for at least the period of a year or longer; 
and Stage 3, further treatment will lead to a plateau of weight gain, representing a 
possible ‘ceiling effect’ of APDs, in which patients will maintain the heavier weight 
with on-going APD treatment.19, 20 For example, first episode psychosis patients 
treated with olanzapine or haloperidol gained weight rapidly during the first 12 weeks 
(mean ± SD: olanzapine, 9.2±5.31 kg; haloperidol, 3.7±4.9 kg), then continued to 
gain weight till a plateau was reached (olanzapine, 15.5±9.6 kg; haloperidol, 7.1±6.7 
kg) at approximately 1 year and weight gain remained at this high level (olanzapine, 
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15.4±10.0 kg; haloperidol, 7.5±9.2 kg) at the end of 2 years.20 The BMI changes 
during the 2 year study period followed a pattern similar to that for weight gain; in the 
olanzapine group the mean BMI increased from 23.6±4.8 (Mean ± SD) at the baseline 
to 26.4±4.6 at 12 weeks,  28.8±4.5 at 1 year, and 28.3±4.0  at 2 years, compared with 
haloperidol group with an increase from 23.9±4.5 at the baseline to 24.8±4.1 at 12 
weeks, 26.2±4.3 at 1 year and 26.6±4.4 at 2 years.20 Several long-term studies 
indicate that some APDs may take a much longer time to reach the plateau.19, 21, 22 
This temporal course is well mimicked in an animal model of olanzapine-induced 
weight gain.23, 24 Although the final weight plateau is often reached after several years, 
accumulated evidence indicates that rapid weight-gain in the first few weeks (Stage 1) 
of APD treatment is a strong indicator for the long-term outcome of weight gain and 
obesity.25-27 Therefore, although the time-course of weight gain has been observed to 
have a similar pattern in various APDs, the exact weight gain time-course induced by 
a specific APD still remains for further research.  
 
Are weight-gain and obesity side-effects of APD dose dependant? To date, the 
possible relationship between APD dosages and associated weight gain has not been 
systematically investigated. Simon and colleagues reviewed publications between 
1975 and 2008 and suggested that olanzapine and clozapine appear to have 
dose/serum concentration-dependant weight gain side-effects.28 For example, Perry 
and colleagues reported associations of weight gain with both olanzapine dosages and 
plasma concentrations.29 More recently, in an 8-week, randomized clinical trial of 
olanzapine 10, 20, and 40 mg (oral) doses in 634 patients with schizophrenia or 
schizoaffective disorder, a significant dose-related change in weight gain was found, 
which suggested higher than standard doses of olanzapine may be associated with 
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greater weight gain compared to standard doses.30 This was supported by a study into 
long-acting olanzapine injection, in which clear dose-dependent changes of weight 
gain were observed; a high dose (300mg every 2 weeks) had a higher weight gain 
than medium (405 mg every 4 weeks) and low (150 mg every 2 weeks) doses in 
schizophrenia patients.31 Risperidone-induced weight gain could be dose related to 
some extent but data are contradictory, while no study assessed risperidone serum 
concentrations in association with weight gain.28 Current evidence indicates that other 
APDs including aripiprazole, amisulpride, quetiapine, sertindole and ziprasidone have 
no dose-related metabolic effects, however no study assessed serum concentration of 
these APDs.28 Therefore, prescribing the lowest possible effective doses, at least for 
clozapine, olanzapine and risperidone, will be helpful in minimising the weight gain 
side-effect. 
 
THE EFFECTS OF ANTI-PSYCHOTIC MEDICATION ON 
APPETITE/FOOD INTAKE 
Theoretically, body weight gain results from imbalance between energy intake and 
energy expenditure, in which both over eating and/or less energy expenditure (such as 
decreasing resting metabolism and activity) may contribute to overweight and obesity. 
Over the past 15 years, accumulated data from both clinical and animal studies 
suggest that increasing appetite and food intake, as well as delayed satiety signalling, 
are key behavioural changes related to APD-induced weight gain/obesity.32-34  On the 
other hand, there is less understanding of to what extent changes of resting 
metabolism rate and activity/sedation affect weight gain associated with APD 
medication, although current evidence suggests that they may play an important role 
in the development of APD-induced weight gain.19, 35, 36 
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Altered eating behaviours have been reported in a number of clinical studies with 
treatment involving various APDs. Gothelf and colleagues first reported that 
increased food intake, but not resting energy expenditure and physical activity, was 
associated with olanzapine-induced weight gain in schizophrenia patients.37 A 
randomized double-blind study has found that both clozapine and olanzapine are 
associated with food craving and binge eating over the 6-week treatment period.38 
Compared to those with clozapine, patients receiving olanzapine tended to have 
higher rates of food craving  (olanzapine 48.9% vs clozapine 23.3%) and binge eating 
(olanzapine 16.7% vs clozapine 8.9%), which also occurred earlier (1 week vs 3 
weeks for binge eating).38 Eating behaviour in patients treated with atypical APDs 
(clozapine, olanzapine, risperidone, quetiapine or ziprasidone) were also compared 
with health controls by recording appetite sensation before and after a standardized 
breakfast using visual analogy scales, and found that: (1) atypical APD-treated 
patients showed greater adiposity and a higher degree of hunger following the 
standardized breakfast; and (2) patients had significantly higher cognitive dietary 
restraint, disinhibition, and susceptibility to hunger than controls.33 The patients 
treated with atypical APDs were also more reactive to external eating cues.34 
Furthermore, a recent study reported that, consistent with the significant increase of 
body weight, food consumption and disinhibited eating, one week treatment with 
olanzapine enhanced both the anticipatory and consummatory reward response to 
food rewards in the brain reward circuitry, including the inferior frontal cortex, 
striatum and anterior cingulate cortex, but decreased activation in the brain region (the 
lateral orbital frontal cortex) thought to inhibit feeding behaviour.39 
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These clinical findings are confirmed in animal studies that APD-induced 
hyperphagia is repeatedly found in animal models of APD-induced weight gain.23, 40-43 
Furthermore, recently olanzapine has been found to selectively increase rat’s 
responding to sucrose pellets in an operant conditioning without affecting free-
feeding intake of sucrose; in contrast sibutramine (a noradrenaline/serotonin reuptake 
inhibitor and a weight reducing agent) prevented the increase of rat’s responding to 
sucrose pellets induced by olanzapine.44 It has been well established that the 
hypothalamic arcuate nucleus (Arc) plays a crucial role in appetite and energy 
homeostasis through activation of two distinct populations of anorexigenic and 
orexigenic neurons: neurons that express appetite inhibiting cocaine- and 
amphetamine-related transcript (CART) and pro-opiomelanocortin (POMC), and 
neurons that express appetite stimulating agouti-related peptide (AgRP) and 
neuropeptide Y (NPY).45 Using the animal model for olanzapine-induced weight gain, 
it has been revealed that olanzapine elevated expression of appetite stimulating AgRP 
and NPY and decreased appetite inhibiting POMC.46, 47 These results suggest that 
patients treated with APDs may develop abnormal eating behaviours in response to 
altered appetite sensations and increased susceptibility to hunger which may lead to a 
positive energy balance and contribute to body weight gain.  
 
INSULIN RESISTANCE, GLUCOSE DYSREGULATION, AND DIABETES 
ASSOCIATED WITH ANTI-PSYCHOTIC MEDICATION 
Effects of atypical APDs. Validated evidence over the past 20 years has indicated 
that APD medication significantly increases the risk of insulin resistance, glucose 
dysregulation and the development of T2DM.5, 48, 49 Although patients with 
psychiatric disorders such as schizophrenia have been observed to have an increased 
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risk  of developing diabetes regardless of antipsychotics, suggesting that the disease 
itself may be a predisposed risk factor,50-52 APD medication has been widely 
recognized as a main contributor for these metabolic disorders.48, 49 An analysis of the 
US FDA Adverse Event database also showed that adjusted report ratios for T2DM 
were the following: olanzapine 9.6 (95% confidence interval (CI) 9.2-10.0), 
risperidone 3.8 (3.5-4.1), quetiapine 3.5 (3.2-3.9), clozapine 3.1 (2.9-3.3), ziprasidone 
2.4 (2.0-2.9), aripiprazole 2.4 (1.9-2.9), and haloperidol 2.0 (1.7-2.3), which suggests 
differential risks of diabetes across various APDs.53 
 
Owing to relatively short trial periods, many clinical trials have not been able to 
capture most new cases of diabetes, however numerous studies have shown strong 
relationships between APDs and indicators of insulin resistance and glucose 
dysregulation.48, 54 In the CATIE study in chronic schizophrenia patients, fasting 
blood glucose (FBG) was most elevated compared to baseline with olanzapine 
(15.0±2.8 mg/dl; mean ± standard error), followed by quetiapine (6.8±2.5 mg/dl), 
risperidone (6.7±2.0 mg/dl), perphenazine (5.2±2.0 mg/dl), and least elevated with 
ziprasidone (2.3±3.9 mg/dl).17  The EUFEST study has reported a similar incident rate 
of hyperglycemia among various APDs after one year treatment with haloperidol 
(18%), amisulpride (21%), olanzapine (30%), quetiapine (22%) and ziprasidone 
(22%), with a significant increase of fasting insulin level (haloperidol 2.0±1.4 mU/L, 
amisulpride 8.6±3.1 mU/L, olanzapine 2.5±3.9 mU/L, quetiapine 2.1±1.2 mU/L and 
ziprasidone 0.1±2.0 mU/L).15 Chronically elevated insulin levels and concurrent 
hyperglycemia are consistent with insulin resistance, and may indicate T2DM.55 In 
fact, numerous clinical studies have reported that chronic APD treatment increases 
insulin-resistance. Using the homeostasis model assessment (HOMA) index for 
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insulin resistance (HOMA-IR), chronic (8 weeks to 5 months) treatment with 
olanzapine, clozapine and risperidone has been repeatedly reported to significantly 
increase HOMA-IR,56-61 although risperidone was normally observed to have a lesser 
effect on HOMA-IR.58, 60, 61 Furthermore, patients with chronic olanzapine treatment 
also showed a greater decrease in insulin sensitivity during an oral glucose tolerance 
test (OGTT) than those treated with risperidone.61 Using a frequently sampled 
intravenous glucose tolerance test and minimal model analysis, significant insulin 
resistance and impairment of glucose effectiveness were reported in non-obese 
patients chronically treated with clozapine and olanzapine, but with a lesser effect in 
patients treated with risperidone and quetiapine.62, 63 Recently, a two-step 
euglycaemic, hyperinsulinaemic clamp procedure has been used to assess changes in 
insulin sensitivity in non-diabetic patients with schizophrenia or schizoaffective 
disorder treated with olanzapine or risperidone; it was found that both olanzapine and 
risperidone treatment caused a decrement in insulin sensitivity.59 These results were 
confirmed in numerous animal studies using the HOMA-IR index or 
euglycaemic/hyperinsulinaemic clamp procedures: chronic treatment with olanzapine 
and clozapine caused insulin resistance, reduced insulin sensitivity and glucose 
dysregulation.64-68  
 
The effects of APDs using haloperidol as an example. Although over the past 15 
years the metabolic side-effects of atypical APDs have attracted most of the attention, 
there is evidence that treatment with some typical APDs also increases the risk of 
insulin resistance, glucose dysregulation and T2DM.11, 49, 69, 70 Since they were 
introduced to the clinics in the 1950s, chlorpromazine and thioridazine have been 
repeatedly reported to cause abnormal glucose tolerance, insulin resistance and even 
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T2DM.70-76 On the other hand, it was generally believed that haloperidol did not 
increase the risk of insulin resistance and T2DM,49 however recent evidence from 
clinical trials in first episode patients showed that haloperidol may have a higher risk 
than originally thought. As discussed above, the EUFEST study has reported that one 
year treatment of haloperidol has a similar incident rate of hyperglycemia and 
increased fasting insulin levels to atypical APDs olanzapine and quetiapine.15 Another 
randomized, double-blind trial in first episode schizophrenia patients also found that 
both FBG and 2 hour post-prandial blood glucose (PPBG) were significantly 
increased by a 6-week treatment with haloperidol (FBG, 6.8±14.1/dl, mean ± standard 
deviation; PPBS, 6.7±12.6 mg/dl), olanzapine, (FBG, 6.6±12.7mg/dl; PPBS, 
21.5±32.2 mg/dl) and risperidone (FBG, 4.3±12.5 mg/dl; PPBS, 21.0±23.4 mg/dl), 
with a similar incidence rate of diabetes induced by APD treatment (haloperidol 9.7%, 
olanzapine 11.4%, risperidone 9.1%) by WHO criteria.69 A one year treatment of 
haloperidol in drug-naïve first episode patients showed a similarly increased insulin 
level and insulin resistance index (HOMA-IR) as olanzapine and risperidone.77 
Analyzing data from the Italian Health Search Database also showed that, in initially 
non-diabetic and APD-free patients, the diabetic risk ratios were 12.4% (95% CI 6.3-
24.5) for haloperidol, 18.7% (8.2-42.8) for risperidone, 20.4% (6.9-60.3) for 
olanzapine, 33.7% (9.2-123.6) for quetiapine, and no significant difference between 
various drug groups.78 These findings were confirmed by a large population-based 
study conducted in Denmark, which included 345,937 patients treated with an APD 
and 1,426,488 unexposed control subjects: a significantly higher relative risk 
compared with the general population was observed in drug-naïve patients treated 
with olanzapine (1.35, 95% CI 1.18-1.54), risperidone (1.24, 95% CI 1.09-1.40), 
sertindole (9.53, 95% CI 1.34-67.63), perphenazine (1.60, 95% CI 1.45-1.77), 
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ziprasidone (3.09, 95% CI 1.54-6.17), and haloperidol (1.32, 95% CI 1.17-1.49), but 
not in patients treated with aripiprazole, amisulpride or quetiapine.79 These results 
suggest that treatment with haloperidol, like chlorpromazine and thioridazine, is 
associated an increased risk of glucose and insulin deregulation. 
 
Indirect effects of APD-induced weight gain and obesity vs direct effects of APDs 
on insulin resistance and glucose dysregulation. Given the well-established 
association between obesity and insulin resistance and hyperglycemia, APD-induced 
dysregulation of glucose homeostasis has been frequently linked to the high weight 
gain and obesity propensity of these drugs. For example, many studies have found the 
increased HOMA-IR induced by chronic treatment of olanzapine, clozapine or 
risperidone was correlated with weight gain/adiposity.58, 77, 80 Weight gain and 
adiposity were also found to be significantly correlated with changes in insulin 
sensitivity in patients following a 12 week treatment with olanzapine and 
risperidone.59 Recently, Kim et al. reported that body mass index contributed a quarter 
to a third of the variance in insulin resistance in olanzapine-treated patients.81 
However, growing evidence demonstrated that treatment with APDs, particularly 
short-term treatment, can directly affect insulin resistance and glucose homeostasis 
independent of weight gain.82 In fact, clinical studies have shown impaired glucose 
regulation in some schizophrenia patients treated with APDs without weight gain.83 
Insulin resistance has also been reported to be induced by olanzapine treatment within 
days without weight gain.84, 85 Diabetic ketoacidosis has been reported in patients in 
early treatment with various APDs and without weight gain.86 In APD-naïve 
schizophrenia patients, two weeks’ treatment of olanzapine decreased insulin 
secretory response to a hyperglycemic challenge, which suggests that olanzapine 
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might directly impair pancreatic β-cell function.87 Data from animal studies also 
showed that acute treatment, even a single acute dose, of olanzapine, risperidone or 
clozapine can cause hyperglycemia and hyperinsulinemia, impair insulin-sensitivity, 
and induce insulin-resistance.66, 88-91 An in vitro study also showed that olanzapine 
and clozapine can directly decrease glucose-stimulated insulin secretion from 
pancreatic β cells.92 Furthermore, olanzapine and clozapine can significantly decrease 
the insulin-stimulated glucose transport rate by about 40% in 3T3-L1 adipocytes, 
whereas clozapine and risperidone reduced the insulin-stimulated glucose transport 
rate by about 40% in primary cultured rat adipocytes.93 Therefore, these typical APDs 
may directly induce insulin resistance by directly impairing insulin-responsive 
glucose resistance in adipocytes.93  
 
Time course of APD-induced insulin dysregulation. Although a growing body of 
evidence has shown that short-term/acute APD treatment decreases fasting plasma 
insulin levels and attenuates glucose-stimulated insulin response,87, 88, 91, 94 as 
discussed above, chronic treatment is associated with hyperinsulinemia, insulin-
resistance and T2DM.49, 59, 95 The apparent conflict in reports between chronic and 
short-term APD treatment may be reconciled by a hypothesis of time-dependent 
changes of APD-induced insulin dysregulation. This hypothesis is supported by a 
recent report that found time-dependent changes of glucose-stimulated insulin 
response in individuals with schizophrenia: decreased insulin levels during the first 2 
weeks’ olanzapine treatment compared to their baseline levels, followed by a return to 
baseline levels after 4 weeks’ treatment, and increased insulin response following 8 
weeks’ olanzapine treatment.96 In another study in schizophrenia patients who started 
or switched to a different APD for 3 months, a time-dependent worsening of plasma 
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glucose levels was observed in subjects taking clozapine, olanzapine and quetiapine.97 
A recent animal study also demonstrated that acute treatment of rats with olanzapine 
showed both glucose dysregulation and insulin resistance, however rats treated 
intermittently with olanzapine (once per week) showed a marked worsening in both 
glucose dysregulation and insulin resistance over the time course of a 10 week 
treatment.67 The mechanisms underlying this time-dependent change of APD-induced 
insulin and glucose dysregulation have not been investigated however.  
 
NEUROPHARMACOLOGICAL MECHANISMS FOR APD-INDUCED 
WEIGHT GAIN AND GLUCOMETABOLIC SIDE-EFFECTS 
In contrast to typical APDs (such as haloperidol) that are largely potent and selective 
D2 antagonists, atypical APDs have binding affinities for various neurotransmitter 
receptors, such as dopamine D2, serotonin 5HT2A and 5HT2C, adrenergic α1-2, 
muscarinic M1 and M3 and histamine H1 receptors98 Among these receptors, dopamine 
D2 and 5-HT2 receptors play critical roles in the therapeutic effects of atypical 
APDs.99, 100 Accumulated evidence has revealed that the antagonistic properties of 
5HT2C and H1 receptors are involved in APD-induced weight gain.32, 101, 102 In fact, 
among APDs, clozapine and olanzapine have the highest affinities for 5HT2C and H1 
receptors, and have the highest risk of weight gain and obesity side-effects.36, 98, 103 
Therefore, the neuropharmacological mechanisms reviewed here are mainly from 
studies in olanzapine and clozapine. It is worth noting that, due to the variations in 
receptor binding profiles between different APDs, the mechanisms underlying the 
weight gain and glucometabolic side-effects might not be exactly the same between 
various APDs. 
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Over the past thirty years the 5-HT receptor has been revealed to regulate appetite and 
body weight, mainly through acting at the hypothalamic 5-HT2C receptors.104 In fact, 
5-HTergic neurons project to the hypothalamic POMC neurons that co-express 5-
HT2C receptors, and 5-HT has been found to influence appetite by activating 
anorexigenic POMC neurons and melanocortin 4 receptors.104 Considering the finding 
that olanzapine decreases expression of POMC in animal studies.46, 47 APDs may 
therefore increase appetite by inhibiting POMC neurons through the 5-HT2C 
receptors. It is interesting that 5-HT2C agonists reduce food intake by advancing 
satiety, and these effects are reversed by 5-HT2C antagonists.105, 106 These results 
suggested that blockade of 5-HT2C receptors could possibly be the mechanism for the 
clinical findings that the treatment with both clozapine and olanzapine could induce 
food craving and binge eating in patients.38 Furthermore, the role of 5-HT2C in APD-
induced weight gain was confirmed by an animal study which showed that the initial 
(5 days) increase in weight gain and food intake associated with olanzapine treatment 
could be mimicked by combining a 5-HT2C antagonist (SB243213) with haloperidol, 
but not by an H1 antagonist alone or combined with haloperidol.107 However, there is 
clear evidence that 1-week and 12 weeks treatment with olanzapine reduces the 
expression of hypothalamic H1 receptors, and H1 receptor changes have been 
correlated with increased food intake and weight gain in rats.24 Olanzapine and 
clozapine have been reported to activate hypothalamic AMPK pathway via H1 
receptors to increase food intake and body weight gain.108 Olanzapine has also been 
reported to regulate feeding behaviour in rats by modulating histaminergic 
neurotransmission.109 The role of the H1 receptor in APD-induced weight gain has 
also been supported by findings that co-treatment of betahistine (an H1 agonist and an 
H3 antagonist) can significantly reduce olanzapine-induced weight gain in both 
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schizophrenia patients and animals.110-112 It has also been postulated that different 
neural mechanisms are responsible for the three stages of weight gain induced by 
APDs.19 
 
APD affinity for the Muscarinic M3 receptor has been identified as most closely 
linked to its diabetic side-effects.113-115 and can even be used to predict its 
diabetogenic liability.113 Consistently, olanzapine and clozapine, two of the APDs 
associated with a high risk of insulin resistance, glucose dysregulation and diabetic 
side-effects, possess the highest M3 receptor binding affinity.116 M3 receptors play a 
crucial role in the regulation of insulin secretion through both the peripheral and 
central cholinergic pathways 117. An in vitro study has shown that olanzapine and 
clozapine can impair cholinergic-stimulated insulin secretion.92 A recent animal study 
found that a single subcutaneous injection of darifenacin (a selective M3 muscarinic 
antagonist) significantly decreased insulin response to glucose challenge compared to 
control.118 M3 receptors are widely expressed in the hypothalamic arcuate (Arc) and 
ventromedial (VMH) nuclei, and the dorsal vagal complex of the brainstem, brain 
regions well-documented for their role in insulin and glucagon secretion and glucose 
homeostasis.119, 120 Recently, we found that a 2-week treatment with olanzapine 
decreased fasting insulin levels and correlated with an increase in M3 receptor binding 
density in the Arc, VMH, and DVC.121 In addition, acute central treatment with 
olanzapine via intracerebroventricular infusion induces hepatic insulin resistance and 
increased hypothalamic AMPK expression.122 Results from the two studies suggest 
that olanzapine may block M3 receptor signalling pathways in the brain, thus 
impacting insulin production and insulin resistance. Therefore, APDs may act through 
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both peripheral and central M3 antagonism to impair compensatory insulin response, 
resulting in diabetes. 
 
Since the introduction of APDs in the 1950s, binding at dopamine D2 receptors 
(antagonism or partial agonism) remains the only mechanism common to therapeutic 
efficacy of all APDs.100 There is evidence that both atypical and typical APDs can 
cause weight gain and other metabolic side-effects, particularly recent clinical data 
from studies in first episode patients that demonstrated haloperidol (a potent and 
selective D2 antagonist) is associated with weight gain, insulin resistance, glucose 
dysregulation side-effects as discussed above; it is therefore reasonable to propose D2 
receptors as a possible common mechanism underlying these side-effects. Although it 
has been the subject of fewer investigations, there is some evidence supporting the 
involvement of D2 receptors in APD-induced weight gain, insulin resistance, glucose 
dysregulation side-effects. As discussed above, only combined treatment of a 5-HT2C 
antagonist with haloperidol can mimic olanzapine-induced weight gain.107 A 
relationship between a functional promoter region polymorphism in DRD2 and weight 
gain induced by olanzapine and risperidone has reported in first episode 
schizophrenia.123 Dopamine and D2 receptors are key components of the reward 
system controlling desire for food and hence body weight regulation.124 Our previous 
study found that D2 receptor density was significantly lower in the rostral part of the 
caudate putamen in obese mice compared to lean mice.125 It is well established that 
blockade of dopamine D2 receptor activity in the mesolimbic and nigrostriatal 
pathways is the common mechanism of APD action,100, 126 these pathways are also 
key pathways for food reward.127 In fact, a reduced striatal activation was detected by 
fMRI during reward anticipation due to appetite-provoking in chronic schizophrenia 
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with APD treatment.128 Therefore, APDs may increase appetite and food intake by 
acting on dopamine D2-mediated reward.127 It is interesting that D2-like receptors are 
also expressed in pancreatic β-cells which function to inhibit glucose-stimulated 
insulin secretion,129 and permanent lack of D2 receptor mediated inhibition (such as in 
D2 knock out mice Drd2-/-) eventually results in glucose intolerance.130 It has been 
reported that a single subcutaneous injection of raclopride (a D2/D3 selective 
antagonist) can enhance insulin secretion and marginally decrease insulin 
sensitivity.118 Therefore, this may provide a mechanism to explain why chronic 
treatment of some typical APDs (such as haloperidol) leads to glucose dysregulation 
hyperinsulinemia, and eventually diabetes.  
 
SUMMARY 
Over the past 20 years, it has been established that treatment with atypical APDs is 
associated with serious weight gain, obesity, and other metabolic side effects such as 
insulin resistance, glucose dysregulation and T2DM, however the metabolic side-
effects associated with some typical APDs are possibly underestimated. Emerging 
evidence over the past 5-6 years from the studies in first episode psychotic and drug 
naïve patients show that some commonly used typical APDs (such as haloperidol) 
may also course significant weight gain, insulin resistance, glucose dysregulation, and 
even T2DM, particularly under chronic treatment. In fact, although some atypical 
APDs, particularly clozapine and olanzapine, have a higher liability than others in 
inducing metabolic side-effects, current evidence has indicated that all APDs have a 
greater weight gain and various metabolic side-effects than placebo-level effects.  
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It is worth noting that variations in weight gain and other metabolic side-effects are 
observed not only among APDs, but the marked individual variations have also been 
observed in all reported clinical studies and that, irrespective of the APD, some 
subjects lose weight, some maintain weight and some gain weight.15, 17 It is also worth 
noting note that not all weight gain is detrimental. For those patients who are 
underweight prior to APD treatment, possibly reflecting that their psychotic illness 
has caused them to neglect themselves, weight gain associated with APD is beneficial 
if the medication results in these individuals returning to a pre-morbid and healthy 
weight.131 This individual variation could be related to both genetic and nongenetic 
factors (such as gender, age and initial body weight/BMI etc.).132, 133 Although there is 
no reliable biomarker for prediction of weight gain, several studies have identified 
female gender, younger age and a low BMI prior to the first APD treatment as risk 
factors for APD-induced weight gain and obesity.133-136 A diagnosis of 
undifferentiated schizophrenia or schizophrenia spectrum disorder was also identified 
as a possible predictor for APD-induced weight gain.133, 136 Since APD-induced 
weight gain has a time-dependent development, and particularly rapid weight gain in 
the first few weeks of APD treatment is a good indicator for a long-term outcome of 
weight gain and obesity,19, 27 weight monitoring during the early phase of APD 
therapy is crucial for prevention of this serious side-effect. It is important to note that 
insulin resistance and glucose dysregulation may develop independently of weight 
gain, therefore monitoring only weight gain is not enough, and a periodic monitoring 
of blood sugar may also be required during APD therapy, particularly for drugs with 
high diabetic liabilities such as olanzapine and clozapine. Although current evidence 
suggests that multiple neurotransmitter receptors such as 5-HT2C, histamine H1, 
muscarinic M3 (and possibly also dopamine D2 receptors), are involved in weight 
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gain/obesity and insulin and glucose dysregulation associated with APDs, one 
important issue that needs to be investigated is how these neurotransmitter systems 
interact during the time-dependent development of these side-effects. An improved 
understanding of the mechanisms underlying the time-dependent development of 
these metabolic side-effects could help in designing better strategies to prevent and 
treat these devastating side-effects and their associated cardiovascular disease, stroke 
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